- Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP-1, NEJM 2021, n=1,961) Jastreboff AM et al
The association of nonalcoholic fatty liver disease, obesity, and metabolic syndrome, with systemic inflammation and subclinical atherosclerosis: the Multi-Ethnic Study of Atherosclerosis (MESA)
This question is especially relevant for individuals who may not be classified as obese but are looking for weight management solutions
BG has received fees for the activities of speaking, scientific advising, or clinical research from Eli Lilly, Novo Nordisk, AstraZeneca, Sanofi, Bristol Myers Squibb, Novartis, GlaxoSmithKline, Johnson & Johnson, Bayer, Intercept Pharma France, Gilead, Boehringer Ingelheim, Janssen, Intarcia, MetaCure, Pfizer, Merck Sharp & Dohme, Roche Diagnostics, Medtronic, Insulet, A